The combination of S63845 with venetoclax, which is a FDA-approved BCL-2 inhibitor, has potent activity against nasopharyngeal carcinoma, acute myeloid leukemia, and mantle cell lymphoma without severe toxicity26,41,42. Here, BCL2 is linked to nasopharyngeal carcinoma.